Challenges & Opportunities for CABG Surgery
Executive Summary
Recent safety issues with drug-eluting stents may have opened the door ever so slightly for cardiac surgeons and coronary artery bypass graft (CABG) surgery to stage a small but noticeable comeback in the treatment of coronary artery disease.
You may also be interested in...
Estech: Back From the Brink
Estech, a small cardiac surgery and surgical ablation company, figured it had its strategy all set: after taking an investment from Boston Scientific, it would ramp up commercialization and, once it hit a certain sales target, would be acquired by BSC. But when Boston itself changed its strategy around the small companies in which it had made investments, Estech found itself in trouble.
Estech: Back From the Brink
Estech, a small cardiac surgery and surgical ablation company, figured it had its strategy all set: after taking an investment from Boston Scientific, it would ramp up commercialization and, once it hit a certain sales target, would be acquired by BSC. But when Boston itself changed its strategy around the small companies in which it had made investments, Estech found itself in trouble.
ESC Highlights: Imaging, Hypertension Devices Take Center Stage
This year's European Society of Cardiology Congress drew cardiologists from across the globe to packed sessions. While drug-eluting stent reports were a mixed bag, remote catheter navigation explored new frontiers and emerging hypertension devices were a major draw.